Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finamine PK and Tolerance Study in Healthy Chinese Adults
NCT04162275Phase 1Completed
- Sponsor
- Yiling Pharmaceutical
- Start
- Aug 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Finamine in Parkinson's disease (PD) (6 arms), sponsored by Yiling Pharmaceutical. Primary endpoints: Tolerance evaluation, Adverse Events and 5 more. Started Aug 2017; status: completed.
02
Drugs
Finamine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04162275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04162275.